TITAN.

Headline: Johnson & Johnson isn’t going to let Astellas pull a fast one on them. TBL: Just like enzalutamide, apalutamide in addition to ADT for metastatic castrate-sensitive prostate cancer significantly prolongs survival when compared to placebo in the phase 3 TITAN trial. | Chi, N Engl J Med 2019